Survodutide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor co-agonist under clinical investigation, developed as a single peptide molecule with agonist activity at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). The compound's pharmacological rationale differs from incretin-based approaches: glucagon receptor activation promotes hepatic fat oxidation and energy expenditure, while simultaneous GLP-1 receptor engagement provides satiety and insulin secretagogue effects — positioning the combination as a research tool for examining hepatic and systemic metabolic pathways simultaneously.
Preclinical studies in rodent models of diet-induced obesity and non-alcoholic steatohepatitis (NASH) have examined survodutide's effects on liver fat content, inflammatory markers, and fibrosis-related endpoints. GCGR activation distinguishes survodutide from GLP-1/GIP dual agonists such as tirzepatide, providing a distinct mechanistic lens for studying the glucagonergic contribution to hepatic metabolism — an area of particular interest in MASH (metabolic dysfunction-associated steatohepatitis) research.
PeptidesFromChina.co supplies survodutide as a lyophilized powder in sealed vials at 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis accompanies every batch. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | GLP-1/glucagon dual receptor agonist (unimolecular) |
|---|---|
| Synonyms | BI 456906 |
| Receptor Targets | GLP-1R (glucagon-like peptide-1 receptor), GCGR (glucagon receptor) |
| Molecular Weight | ~3.5 kDa (acylated peptide) |
| Research Areas | Hepatic metabolism, NASH/MASH research, metabolic disorders, dual-receptor pharmacology |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (use promptly) |
| CAS Number | 2244817-06-7 |
| Molecular Formula | N/A — acylated peptidomimetic; see COA |
| Sequence | Available on COA (GLP-1/glucagon dual agonist sequence) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Survodutide | 10 mg | 10 vials | ≥98% | In Stock | $363.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Research into survodutide focuses on how simultaneous GLP-1R and GCGR activation affects metabolic outcomes compared to selective GLP-1R agonism alone. Glucagon receptor signaling promotes hepatic glycogenolysis and fat oxidation — typically viewed as counterproductive in metabolic disease — but in the context of caloric restriction and GLP-1-mediated insulin secretion, studies have examined whether glucagonergic input provides additive benefits to energy expenditure and hepatic lipid clearance.
One of the primary research applications for survodutide is MASH (metabolic dysfunction-associated steatohepatitis), formerly NASH. Glucagon receptor activation's ability to promote fatty acid oxidation in the liver has made dual GLP-1/glucagon agonists of particular interest in this indication. Preclinical studies have examined liver fat content reduction, inflammatory marker changes (AST, ALT), and fibrosis scoring in steatohepatitis models.
Survodutide provides researchers with a mechanistic counterpart to GLP-1/GIP dual agonists. While GIP receptor activation primarily affects adipose tissue insulin sensitivity and incretin release, glucagon receptor activation has a distinct hepatocentric profile. Studies comparing GLP-1/GCGR versus GLP-1/GIPR strategies in matched preclinical models are of significant research interest for understanding organ-specific metabolic regulation.
Both are dual agonists, but at different receptor pairs. Tirzepatide targets GLP-1R and GIPR (incretin receptors). Survodutide targets GLP-1R and GCGR (glucagon receptor). The glucagon receptor component gives survodutide a hepatic fat oxidation mechanism that is absent in tirzepatide — making it a distinct tool for liver metabolism research.
Glucagon receptor activation promotes hepatic fatty acid oxidation and can reduce liver fat content — a primary target in MASH. Combined with GLP-1R engagement (which provides satiety and insulin secretion effects), the dual mechanism is hypothesized to produce hepatic benefits beyond what GLP-1R agonism alone achieves.
Survodutide is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facility is included with every batch.
Lyophilized survodutide should be stored at −20°C, protected from light and moisture. Reconstituted solutions should be kept at 2-8°C and used promptly.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.